Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
Open Access
- 1 February 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 8 (2) , 449-457
Abstract
Differentiation is a complex set of events that can be blocked by rearrangements of regulatory genes producing fusion proteins with altered properties. In the case of myxoid liposarcoma (MLS) tumors, the causative abnormality is a fusion between the CHOP transcription factor and the FUS or EWS genes. CHOP belongs to and is a negative regulator of the large CAAT/enhancer binding protein family whose α, β,and δ members are master genes of adipogenesis. Recent clinical data indicate a peculiar sensitivity of these tumors to the natural marine compound trabectedin. One hypothesis is that the activity of trabectedin is related to the inactivation of the FUS-CHOP oncogene. We find that trabectedin causes detachment of the FUS-CHOP chimera from targeted promoters. Reverse transcription-PCR and chromatin immunoprecipitation analysis in a MLS line and surgical specimens of MLS patients in vivo show activation of the CAAT/enhancer binding protein–mediated transcriptional program that leads to morphologic changes of terminal adipogenesis. The activity is observed in cells with type 1 but not type 8 fusions. Hence, the drug induces maturation of MLS lipoblasts in vivo by targeting the FUS-CHOP–mediated transcriptional block. These data provide a rationale for the specific activity of trabectedin and open the perspective of combinatorial treatments with drugs acting on lipogenic pathways. [Mol Cancer Ther 2009;8(2):449–57]Keywords
All Related Versions
This publication has 32 references indexed in Scilit:
- Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743Proceedings of the National Academy of Sciences, 2007
- Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)Blood, 2006
- The Myxoid/Round Cell Liposarcoma Fusion Oncogene FUS-DDIT3 and the Normal DDIT3 Induce a Liposarcoma Phenotype in Transfected Human Fibrosarcoma CellsThe American Journal of Pathology, 2006
- Understanding mesenchymal cancer: the liposarcoma-associated FUS–DDIT3 fusion gene as a modelSeminars in Cancer Biology, 2005
- Krüppel-like transcription factor KLF5 is a key regulator of adipocyte differentiationCell Metabolism, 2005
- Leukemia-Associated Fusion Proteins: Multiple Mechanisms of Action to Drive Cell TransformationCell Cycle, 2004
- Comparable transforming capacities and differential gene expression patterns of variant FUS/CHOP fusion transcripts derived from soft tissue liposarcomasOncogene, 2004
- Preclinical and clinical results with the natural marine product ET-743Expert Opinion on Investigational Drugs, 2003
- CCAAT/enhancer-binding proteins: structure, function and regulationBiochemical Journal, 2002
- A Novel FUS/CHOP Chimera in Myxoid LiposarcomaBiochemical and Biophysical Research Communications, 2000